AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Prostacyclin in COMBAT-COVID trial restores endothelial barrier integrity, reducing pulmonary edema.
- Low-dose prostacyclin acts by regenerating glycocalyx and tight junctions to improve endothelial health in critical patients.
Deep dives
The Research Background and Rationale for the Trial
Patients with critical illness and endotheliopathy, characterized by endothelial damage markers, were the focus of the study. Preliminary studies showed that low-dose prostacyclin improved biomarkers reflecting endothelial health. Prostacyclin binds to endothelial cell receptors, enhancing endothelial integrity by regenerating glycocalyx and tight junctions, rather than primarily working as an anticoagulant or anti-inflammatory agent.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode